BACKGROUND:Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). AIMS: AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented. METHODS: A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50-80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study. RESULTS: The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively. CONCLUSION: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population. 2007 S. Karger AG, Basel
RCT Entities:
BACKGROUND:Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). AIMS: AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented. METHODS: A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50-80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study. RESULTS: The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively. CONCLUSION: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population. 2007 S. Karger AG, Basel
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright Journal: Am J Kidney Dis Date: 1998-11 Impact factor: 8.860
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: F Kronenberg; P König; U Neyer; M Auinger; A Pribasnig; U Lang; J Reitinger; G Pinter; G Utermann; H Dieplinger Journal: J Am Soc Nephrol Date: 1995-07 Impact factor: 10.121
Authors: Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Hallvard Holdaas; Ingar Holme; Roland E Schmieder; Alan G Jardine; Faiez Zannad; Gudrun E Norby; Bengt C Fellström Journal: J Am Soc Nephrol Date: 2011-05-12 Impact factor: 10.121
Authors: Jeffrey M Saland; Christopher B Pierce; Mark M Mitsnefes; Joseph T Flynn; Jens Goebel; Juan C Kupferman; Bradley A Warady; Susan L Furth Journal: Kidney Int Date: 2010-08-25 Impact factor: 10.612
Authors: David de Gonzalo-Calvo; Pablo Martínez-Camblor; Christian Bär; Kevin Duarte; Nicolas Girerd; Bengt Fellström; Roland E Schmieder; Alan G Jardine; Ziad A Massy; Hallvard Holdaas; Patrick Rossignol; Faiez Zannad; Thomas Thum Journal: Theranostics Date: 2020-07-09 Impact factor: 11.556